Neomatrix of Irvine, Calif., has developed a fully automated, non-invasive device to assess a patient’s risk of developing breast cancer.
The company’s vaccine technology is based on the universal tumor antigen, which has been expressed in all human cancers studied so far.
Sword Diagnostics of Illinois has developed a “next-generation” system to increase the sensitivity (and therefore accuracy) of diagnostic tests.
LAMP (Lysosome-Associated Membrane Protein) is a gene that has been shown to enhance immune response when incorporated into a DNA vaccine.
The company’s SpaceOAR System is designed to temporarily separate organs during radiotherapy so that normal tissues are spared, and to mark tumor resection sites to allow for targeted therapy.
According to the American Heart Association, heart disease is the number one killer of women over age 25–more than the next five causes of death, or all forms of cancer, combined.
Ovatech of Auburndale, Mass., is developing the world’s first non-hormonal, female-controlled contraception device.
The idea of using harmful bacteria to treat disease might strike many as an odd concept.